George Yaghmour MDAssistant Professor of Clinical Medicine, University of Southern California Norris Comprehensive Cancer Center/Keck School of Medicine, University of Southern California, Los Angeles, California
Dr. George Yaghmour is an assistant professor of clinical medicine at the University of Southern California Norris Comprehensive Cancer Center/Keck School of Medicine. He works in the Jane Anne Nohl Division of Hematology in the areas of acute leukemia and allogeneic stem cell transplantation.
Dr. Yaghmour received his medical degree in 2008 from the University of Aleppo Faculty of Medicine in Aleppo, Syria. After coming to the US, he completed his internship in pediatrics in 2010 at Louisiana State University Health Sciences Center School of Medicine in Shreveport. He underwent residency training in internal medicine at Wayne State University/Henry Ford Hospital in Detroit, Michigan. In 2016, he completed a fellowship in hematology and oncology at the University of Tennessee Health Sciences Center and West Cancer Center in Memphis.
Dr. Yaghmour is a member of several professional societies, including the American Society of Clinical Oncology, the American Society of Hematology, the Society of Translational Oncology, and the American Association for Cancer Research. He is the recipient of several notable awards and has published in numerous journals. His interests focus on platelet disorders and thrombosis and anticoagulation, as well as hematologic malignancies/stem cell transplantation and solid tumors.
Speaker bureau: Jazz, Incyte, Astellas, BMS, Secura, blueprintAdvisory board: Gilead, Alexion
Recent Contributions to PracticeUpdate:
- 69-Year-Old Man Diagnosed With RCC Who Experienced Late-Onset Metastasis
- Grade 2 Clear-Cell Renal Adenocarcinoma With Gall Bladder Metastasis
- Measurable Residual Disease Response in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
- Tisagenlecleucel Is Not Superior to Salvage Therapy in B-Cell Lymphoma
- Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation
- Metastatic cRCC Post-Nephrectomy
- Targeted Therapy for AML
- Venetoclax and Hypomethylating Agents in Favorable-Risk AML
- GVHD Outcomes With Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil for Patients Undergoing Stem Cell Transplant